JP2023534923A - SARS-CoV-2を標的にする抗原結合分子 - Google Patents

SARS-CoV-2を標的にする抗原結合分子 Download PDF

Info

Publication number
JP2023534923A
JP2023534923A JP2023500329A JP2023500329A JP2023534923A JP 2023534923 A JP2023534923 A JP 2023534923A JP 2023500329 A JP2023500329 A JP 2023500329A JP 2023500329 A JP2023500329 A JP 2023500329A JP 2023534923 A JP2023534923 A JP 2023534923A
Authority
JP
Japan
Prior art keywords
seq
polypeptide
antibody
cov
sars
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023500329A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023534923A5 (cg-RX-API-DMAC7.html
Inventor
ゲボルグ グリゴリアン,
ジョン イングラハム,
チュク ルン レオン,
ロス スティーブン フェダーマン,
ロビン ジェフリー グリーン,
アレクシス ハイラム ラモス,
ジェンハン タオ,
Original Assignee
フラッグシップ パイオニアリング イノベーションズ シックス,エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by フラッグシップ パイオニアリング イノベーションズ シックス,エルエルシー filed Critical フラッグシップ パイオニアリング イノベーションズ シックス,エルエルシー
Publication of JP2023534923A publication Critical patent/JP2023534923A/ja
Publication of JP2023534923A5 publication Critical patent/JP2023534923A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/102—Coronaviridae (F)
    • C07K16/104—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023500329A 2020-07-06 2021-07-06 SARS-CoV-2を標的にする抗原結合分子 Pending JP2023534923A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063048589P 2020-07-06 2020-07-06
US63/048,589 2020-07-06
US202063070035P 2020-08-25 2020-08-25
US63/070,035 2020-08-25
PCT/US2021/040546 WO2022010921A1 (en) 2020-07-06 2021-07-06 Antigen binding molecules targeting sars-cov-2

Publications (2)

Publication Number Publication Date
JP2023534923A true JP2023534923A (ja) 2023-08-15
JP2023534923A5 JP2023534923A5 (cg-RX-API-DMAC7.html) 2024-07-17

Family

ID=77127097

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023500329A Pending JP2023534923A (ja) 2020-07-06 2021-07-06 SARS-CoV-2を標的にする抗原結合分子

Country Status (8)

Country Link
US (1) US11981725B2 (cg-RX-API-DMAC7.html)
EP (1) EP4175983A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023534923A (cg-RX-API-DMAC7.html)
KR (1) KR20230035350A (cg-RX-API-DMAC7.html)
AU (1) AU2021306709A1 (cg-RX-API-DMAC7.html)
CA (1) CA3183367A1 (cg-RX-API-DMAC7.html)
IL (1) IL299630A (cg-RX-API-DMAC7.html)
WO (1) WO2022010921A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3183367A1 (en) 2020-07-06 2022-01-13 Gevorg GRIGORYAN Antigen binding molecules targeting sars-cov-2
CA3183373A1 (en) 2020-07-06 2022-01-13 Gevorg GRIGORYAN Antigen binding molecules targeting sars-cov-2
KR20230058434A (ko) 2020-08-26 2023-05-03 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 SARS-CoV-2를 표적으로 하는 항원 결합 분자
WO2023173577A1 (zh) * 2022-03-15 2023-09-21 慧壹科技(上海)有限公司 冠状病毒抗体及其用途
IL316848A (en) 2022-05-06 2025-01-01 Generate Biomedicines Inc Antigen-binding molecules targeting SARS-CoV-2
JP2025537301A (ja) 2022-11-13 2025-11-14 ジェネレイト バイオメディシンズ, インコーポレイテッド Sars-cov-2を標的とする抗原結合分子

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006051091A1 (en) * 2004-11-11 2006-05-18 Crucell Holland B.V. Compositions against sars-coronavirus and uses thereof

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004260884B2 (en) * 2003-07-22 2009-11-19 Crucell Holland B.V. Binding molecules against SARS-coronavirus and uses thereof
US7622112B2 (en) 2003-12-05 2009-11-24 Jody Berry Anti-SARS monoclonal antibodies
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US9200079B2 (en) 2004-11-12 2015-12-01 Xencor, Inc. Fc variants with altered binding to FcRn
KR101616758B1 (ko) 2007-12-26 2016-04-29 젠코어 인코포레이티드 FcRn에 대한 변경된 결합성을 갖는 Fc 변이체
MY177098A (en) 2013-08-09 2020-09-05 Astellas Pharma Inc Novel anti-human tslp receptor antibody
MX2017004103A (es) 2014-10-01 2017-07-07 Medimmune Ltd Proteinas de union especificas para el receptor 1 de lipoproteinas de baja densidad oxidadas de tipo lectina (lox1) y sus usos.
CR20180365A (es) 2015-12-16 2018-09-28 Amgen Inc PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS
US20220089752A1 (en) 2019-01-14 2022-03-24 The Regents Of The University Of California Compositions and methods for modulating cellular internalization
AR120698A1 (es) 2019-12-09 2022-03-09 Ablynx Nv Polipéptidos que comprenden dominios variables únicos de inmunoglobulina que se dirigen a il-13 y tslp
US20250263466A1 (en) 2020-02-03 2025-08-21 Vir Biotechnology, Inc. Antibodies against sars-cov-2 and methods of using the same
WO2021156490A2 (en) 2020-02-06 2021-08-12 Vib Vzw Corona virus binders
HUE062777T2 (hu) 2020-02-26 2023-12-28 Vir Biotechnology Inc SARS-CoV-2 elleni antitestek
EP4121454A1 (en) * 2020-03-19 2023-01-25 Imperial College Innovations Limited Coronavirus antibody
US11028167B1 (en) 2020-03-23 2021-06-08 Centivax, Inc. Anti-SARS-Cov-2 antibodies derived from 3bgf
CR20220552A (es) 2020-04-02 2023-01-17 Regeneron Pharma Anticuerpos contra glicoproteína de espícula anti-sars-cov-2 y fragmentos de unión al antígeno
WO2021203053A1 (en) 2020-04-03 2021-10-07 Vir Biotechnology, Inc. Immunotherapy targeting a conserved region in sars coronaviruses
US20230348571A1 (en) 2020-04-06 2023-11-02 Vanderbilt University Cross-reactive coronavirus antibodies and uses thereof
US11192940B2 (en) 2020-04-10 2021-12-07 Adagio Therapeutics, Inc. Compounds specific to coronavirus S protein and uses thereof
BR112022020706A2 (pt) 2020-04-14 2022-11-29 Vir Biotechnology Inc Anticorpos contra sars-cov-2 e métodos de uso dos mesmos
CN115461364B (zh) 2020-04-28 2025-12-16 北京大学 一种抗新型冠状病毒的单克隆抗体及其应用
PH12022500020A1 (en) 2020-05-08 2024-05-06 Vir Biotechnology Inc Antibodies against sars-cov-2
WO2021247925A1 (en) 2020-06-03 2021-12-09 Vir Biotechnology, Inc. Structure-guided immunotherapy against sars-cov-2
CA3183373A1 (en) 2020-07-06 2022-01-13 Gevorg GRIGORYAN Antigen binding molecules targeting sars-cov-2
CA3183367A1 (en) 2020-07-06 2022-01-13 Gevorg GRIGORYAN Antigen binding molecules targeting sars-cov-2
WO2022015573A2 (en) 2020-07-13 2022-01-20 President And Fellows Of Harvard College Sars-cov-2 antigen-binding proteins and uses thereof
US20230058162A1 (en) 2020-07-27 2023-02-23 Igm Biosciences, Inc. Multimeric coronavirus binding molecules and uses thereof
WO2022046888A1 (en) 2020-08-25 2022-03-03 Target Discovery Merger Sub II, LLC Sars-cov-2 associated antibody compositions and methods of use
KR20230058434A (ko) 2020-08-26 2023-05-03 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 SARS-CoV-2를 표적으로 하는 항원 결합 분자
KR20230127305A (ko) 2020-12-29 2023-08-31 발-첨, 리미티드 파트너십 Covid-19에 대한 중화 단일클론 항체
US20240101646A1 (en) 2021-01-22 2024-03-28 Vanderbilt University Sars-cov-2 coronavirus antibodies and uses thereof
WO2022204202A1 (en) 2021-03-23 2022-09-29 Vir Biotechnology, Inc. Antibodies that bind to multiple sarbecoviruses
KR20240035758A (ko) 2021-05-24 2024-03-18 비르 바이오테크놀로지, 인코포레이티드 조작된 폴리펩타이드
WO2022271863A1 (en) 2021-06-23 2022-12-29 Chan Zuckerberg Biohub, Inc. Coronavirus neutralizing compositions and associated methods
WO2023028603A2 (en) 2021-08-27 2023-03-02 Humabs Biomed Sa Engineered compositions
EP4147716A1 (en) 2021-09-10 2023-03-15 Samatva Research Corporation Anti-virus moiety immobilised in a matrix
IL316848A (en) 2022-05-06 2025-01-01 Generate Biomedicines Inc Antigen-binding molecules targeting SARS-CoV-2

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006051091A1 (en) * 2004-11-11 2006-05-18 Crucell Holland B.V. Compositions against sars-coronavirus and uses thereof

Also Published As

Publication number Publication date
IL299630A (en) 2023-03-01
US11981725B2 (en) 2024-05-14
EP4175983A1 (en) 2023-05-10
CA3183367A1 (en) 2022-01-13
AU2021306709A1 (en) 2023-02-09
KR20230035350A (ko) 2023-03-13
WO2022010921A1 (en) 2022-01-13
US20230295275A1 (en) 2023-09-21

Similar Documents

Publication Publication Date Title
US11987616B2 (en) Antigen binding molecules targeting SARS-CoV-2
US11981725B2 (en) Antigen binding molecules targeting SARS-CoV-2
US12473560B2 (en) Antigen binding molecules targeting SARS-CoV-2
US20230357367A1 (en) Antigen Binding Molecules Targeting SARS-CoV-2
KR102748987B1 (ko) 사스-코로나바이러스-2에 특이적으로 결합하는 항체 및 그의 용도
JP2025506172A (ja) コロナウイルスを広く標的とするヒトモノクローナル抗体
JP2024518335A (ja) SARS-CoV-2に対するヒト中和モノクローナル抗体、及びそれらの使用
US20230242623A1 (en) Compositions and methods for the diagnosis and treatment of sars-cov-2 virus infection
JP2025537301A (ja) Sars-cov-2を標的とする抗原結合分子
US11359007B2 (en) Anti-SARS-CoV-2 neutralizing antibodies
WO2020033926A9 (en) Antibodies that bind cd277 and uses thereof
WO2022095996A1 (zh) 抗SARS-CoV-2抗体及其应用
CN116635410A (zh) 靶向SARS-CoV-2的抗原结合分子
CN116547005A (zh) 靶向SARS-CoV-2的抗原结合分子
WO2024155381A1 (en) Antibodies for zika virus
TW202309069A (zh) 糖鏈修飾rbd及其用途
WO2023131262A1 (zh) 特异性结合SARS-CoV-2的抗原结合蛋白
WO2021243185A9 (en) Sars-cov-2 binding agents and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230120

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240708

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240708

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250702

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251001

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20251219